It is not well understood how paracrine communication between basal and luminal cell populations in the mammary gland affects tumorigenesis. During ErbB2-induced mammary tumorigenesis, enriched mammary stem cells that represent a subpopulation of basal cells exhibit enhanced tumorigenic capacity compared with the corresponding luminal progenitors. Transcript profiling of tumors derived from basal and luminal tumorinitiating cells (TIC) revealed preferential loss of the noncanonical Wnt ligand WNT5A in basal TIC-derived tumors. Heterozygous loss of WNT5A was correlated with shorter survival of breast cancer patients. In a mouse model of ErbB2-induced breast cancer, Wnt5a heterozygosity promoted tumor multiplicity and pulmonary metastasis. As a TGFb substrate, luminal cell-produced WNT5A induced a feed-forward loop to activate SMAD2 in a RYK and TGFbR1-dependent manner to limit the expansion of basal TIC in a paracrine fashion, a potential explanation for the suppressive effect of WNT5A in mammary tumorigenesis. Our results identify the WNT5A/RYK module as a spatial regulator of the TGFb-SMAD signaling pathway in the context of mammary gland development and carcinogenesis, offering a new perspective on tumor suppression provided by basal-luminal cross-talk in normal mammary tissue. Cancer Res; 75(10); 1-11. Ó2015 AACR.
Introduction
The canonical Wnt pathway activates b-catenin and is integral in regulating self-renewal of normal stem cells, and the subversion of the canonical Wnt signaling has been implicated in tumorigenesis (1) . In contrast, noncanonical Wnt signaling is characterized by a lack of requirement for b-catenin and has been studied for its role in embryonic patterning, gastrulation, and organogenesis (2) (3) (4) (5) (6) . Moreover, noncanonical Wnt is proposed to antagonize canonical signaling (7) . WNT5A is the archetype of noncanonical Wnt ligand and has both tumor-suppressive and tumor-promoting effects. WNT5A is tumor suppressive in acute myelogenous leukemia (8) , colorectal cancer (9) , breast cancer (10) , and ovarian carcinoma (11) , whereas WNT5A increases aggressiveness in various cancers (6) . In breast cancer, contradictory results have been reported about the expression of WNT5A in breast cancer based on different methods (12) (13) (14) . J€ onsson and colleagues (13) found the decrease in WNT5A expression through cancer progression (14) . WNT5A expression in the developing murine gland is highest in terminal end buds where loss of TGFb signaling correlates with the decrease of WNT5A; in turn, WNT5A mediates the suppressive effect of TGFb during mammary gland development (15) . Inhibition of the TGFb signaling pathway by DNIIR, a dominant-negative mutation TGFb receptor 2 (TGFbR2), led to increased tumor growth and decreased WNT5A expression (10), a similar phenotype as genetic deletion of WNT5A (15) , suggesting that WNT5A is a TGFb-downstream effector and mediates the tumor-suppressive effect of TGFb.
Several major noncanonical receptors for WNT5A have been studied in development and cancer, including RYK, Ror1/2, and Fzd4 (16) (17) (18) . RYK is a divergent receptor tyrosine kinase (RTK) with a shortened extracellular Wnt-inhibitory factor domain (19) . Because of unusual substitutions in the kinase domain, RYK has an inactive kinase domain and sequesters Wnt ligands from interacting with other receptors (19) . Increased expression of RYK has been linked to poor outcomes in ovarian cancer (20) . RTK-like orphan receptors (ROR) have been studied for their role in embryonic patterning, musculoskeletal, and neuronal development (21). ROR1 and ROR2 have growing evidence for their role in the progression of malignancies (18, 21) .
Our findings demonstrate a novel regulatory mechanism for the TGFb-SMAD signaling pathway via WNT5A. The induction of SMAD2 phosphorylation and activation by WNT5A depends on TGFbR1 kinase activity and RYK. These findings add an avenue to understand the complex environment during mammary tumorigenesis.
Materials and Methods

Mouse illumina array
Tumors were generated from our previous study (22) . RNAs were isolated from tumors (QIAGEN) and their quality was assessed. RNA was submitted to the Genomics Division of the University of Iowa for microarray analysis. Microarray data (GEO accession number: GSE64487) were normalized and transformed into log 2 expression. Transcriptome heatmap and the heatmap for differentially expressed genes were generated in R using the gplots package. The volcano plot was made in R using the ggplot2 package. Fold change was found by the average log 2 expression difference in paired basal tumor-initiating cell (TIC) and luminal TIC tumors. Genes highlighted in the volcano plot have a P value of <0.05 and an average log 2 change ! 1.58 (equal to linear 3.0-fold change).
The Cancer Genome Atlas data analyses
The UCSC Cancer Genome Browser (https://genome-cancer. ucsc.edu) was used to assess copy-number variations (CNV) across all available cancer datasets in The Cancer Genome Atlas (TCGA; ref. 23) . Level 3 Illumina HiSeq 2000 RNAseq for TCGA breast cancer cohort was used. RNAseq expression data were transformed as log 2 (x þ 1) Differences in sample numbers between figures were a result of sorting by categorical data.
Immunohistochemistry
Paraffin embedded tissues were deparaffinized and antigens were retrieved with Antigen Unmasking Solution (Vector Laboratories) or with S1700 (Dako). WNT5A antibody (Genetex) was used at a 1:200 dilution. We consulted with Dr. Ryan Askeland who is a clinical pathologist and defined the intensity of WNT5A staining. The staining intensity of WNT5A was given a scoring system as 0, 1þ, 2þ, and 3þ. For example, we defined the strongest signal as 3þ (an example would be the Fig. 3A , adjacent normal tissues) and the signals equivalent to IgG nonimmune antibody control as 0. We combined 0 and 1þ as low, 2þ as medium, and 3þ as high.
Separation of mammary epithelial cells and spheroid growth in Matrigel
We followed previously established protocols (24) and also included the detailed protocol in Supplementary Methods. Briefly, mammary glands were sequentially digested. Single cells were labeled with a cocktail of antibodies for flow cytometry to separate different epithelial cells. For spheroid growth on Matrigel (BD Biosciences), 1,000 cells were seeded onto Matrigel-coated 8-well chamber slide (24) . Spheroids were photographed 3 weeks later as before (22) and the size was quantitated (25) .
Cells
HMLE cells (provided by Dr. Jing Yang, University of California, San Diego, San Diego, CA) and MCF10A cells (purchased from the ATCC) were maintained using 10% FBS-containing F12 media (Life Technologies) supplemented with insulin (10 mg/mL), hydrocortisone (2 mg/mL), and EGF (10 ng/mL). For both cell lines, we constantly monitored their morphology, confirmed their epithelial cell feature by positive cytokeratin 5 or 8 staining, and further confirmed their identity with three-dimensional spheroid growth. Primary mammary epithelial cells, including basal and luminal mammary epithelial cells, were cultured using EpiCult-B medium (StemCell).
shRNA and siRNA cDNAs of two-independent shRNAs for RYK were constructed into lentiviral vector pLSLPw-GFP with targeting sequences: shRNA-1: 5 0 -GC ACA TTT GTC TTC CAG AA-3 0 ; shRNA-2: 5 0 -CC TGT ACT GGC AAA GTA GA-3 0 . Viral particles were packaged, following by infection of MCF10A cells and purification of GFPpositive cells using flow cytometry (26) . siRNAs for TGFbR1 (siCON, si-1, and si-3 used in Fig. 6B , no targeting information released) were purchased (Sigma-Aldrich).
Cell lysates, immunoprecipitation, immunoblots, and antibodies
Cells were lysed in cell lysis buffer (50 mmol/L Tris-HCL pH7.5, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 100 mmol/L KCl, 50 mmol/L NaF, 10 mmol/L Na 2-glycerophosphate, 1 mmol/L Na 3 VO 4 , and supplemented with protease inhibitor set; Roche). For immunoprecipitation, 1 mg cell lysate was used to incubate with 1 mg/mL of antibodies. Immunocomplex was precipitated using protein A/G sepharose (Thermo Fisher Scientific). Antibodies used are as follows: anti-p-SMAD2/3, anti-p-JNK1/2, and anti-TGFbR1 (Cell Signaling Technology); anti-SMAD1/2/3, anti-JNK1/2, and anti-RYK antibodies (Santa Cruz Biotechnologies); anti-WNT5A (Genetex); and anti-a-tubulin (Sigma-Aldrich); anti-keratin 8 (clone TROMA-I, Developmental Studies Hybridoma Bank at the University of Iowa, Iowa City, IA).
Murine models
All mice were maintained according to Statistical analysis and data presentation Data are presented as mean AE SEM for most studies or mean values AE 95% confidence interval (CI) for genomic data. Microarray data are reported as log 2 . TCGA RNAseq data are reported in log 2 (x þ 1). The Welch T test was used for genomic results. The Student T test was used for the remaining experiments. The Mantel-Cox log-rank test was used for survival curve analysis (Prism v6; GraphPad). Gene expression of human mammary gland cell populations used GEO37223 using normalized expression (30) .
Results
Transcriptome comparison between ErbB2-induced tumors from different TICs
Our previous work has demonstrated a variance in tumorigenic capacity in different mammary epithelial populations of MMTV-ErbB2 mice (22) . CD24 med CD49f hi basal cells (basal TIC) gave rise to larger tumors at a greater incidence than CD24 hi CD49f lo CD61 þ luminal progenitors (luminal TIC). We performed transcript profiling using three-paired tumor samples, with each pair of basal TIC-, or luminal TIC-formed tumors from the contralateral inguinal mammary glands of the same mouse to minimize differences from the recipient mouse. Basal TIC tumors were clustered together with similar gene-expression pattern and separated from luminal TIC tumors (Fig. 1A) . We used a threshold of 3-fold change (log 2 change 1.58) and a P value of less than or equal to 0.05, and found 55 genes meeting the criterion as shown in the volcano plot (Fig. 1B) . Among these genes, we found 28 upregulated and 27 downregulated genes in basal TIC tumors when compared with their paired luminal TIC tumors (Supplementary  Table S1 ; Fig. 1C ). We validated the array dataset by real-time PCR using a panel of 13 upregulated genes ( Supplementary  Fig. S1A ) and 11 downregulated genes ( Supplementary Fig.  S1B ) in basal TIC tumors and nearly all examined genes exhibited similar patterns. We searched the literature and found many genes with known function in cancer (Supplementary Table S1 ). Gene Set Enrichment Analysis (GSEA; ref. 31 ), a computational method that determines whether a defined set of genes show concordant differences between biologic states, revealed that eight pathways related to cellcycle progression, five pathways related to RNA/Protein synthesis and processing, and three pathways related to metastasis and poor prognosis were upregulated in basal TIC tumors (Fig. 1D , other pathways not shown). These data suggest that basal TIC tumors have more aggressive gene signature than luminal TIC tumors.
Wnt5a is lost in more aggressive mouse basal TIC tumors and human breast cancer
In particular, we found Wnt5a to be nearly 6-fold (log 2 difference: 2.534) downregulated in basal TIC mouse tumors compared with luminal TIC tumors (Supplementary Table  S1 ; Fig. 1E ). We identified a similar WNT5A decrease in human breast cancer samples relative to normal tissues in the breast cancer dataset deposited by TCGA ( Fig. 2A) . Lower WNT5A mRNA in breast cancer was significantly correlated with shorter patient survival (Fig. 2B ). Examining the 58 probes of the Infinium HumanMethylation450 methylation data for WNT5A within the TCGA breast cancer, we found no significant correlation between WNT5A expression and DNA methylation (Supplementary Fig. S2A ). Rather, we found that mono-or biallelic loss of WNT5A occurs in 31.1% within the breast cancer dataset and greater than 20% of samples in eight other cancers from TCGA ( Fig. 2C ). Loss of WNT5A was seen in more aggressive subtypes, where 60% of basal-like breast cancer (BLBC), 51% of HER2-positive, and 38% of luminal B have allelic loss, only 18% have allelic loss in the luminal A subtype (Supplementary Table S2 ). The mono-or biallelic loss of WNT5A in breast cancer samples led to decreased WNT5A expression in tumor stages II-IV of breast cancer, but not in stage I ( Supplementary Fig. S2B ). Lower WNT5A mRNA expression was also seen in more aggressive breast cancer subtypes, including luminal B, HER2, and basal-like relative to normal and luminal A subtype (Fig. 2D ). In addition, we found that patients with loss of one WNT5A-allele possessed significantly shorter overall survival (OS) than patients with WNT5A-bialleles (Fig. 2E) .
We observed strong staining of WNT5A at the normal mammary ducts and acini by IHC (Fig. 3A) . Low WNT5A expression was seen in 75% and 60% of samples of triple-negative breast cancer (TNBC) and HER2 subtypes, respectively (Fig. 3B) . In contrast, 75% of estrogen receptor (ER) þ possessed moderate to high WNT5A staining ( Fig. 3A and B) . We noticed a clear luminal distribution of WNT5A in normal mammary ducts (Fig. 3A) . We downloaded GEO dataset GSE37223 (30) and found human luminal cells had approximately 3-fold increase (log 2 difference: 1.733) in WNT5A mRNA relative to basal epithelial cells (Fig. 3C) . We found a similar luminal WNT5A staining in mouse mammary ducts (Fig. 3D, gland) . Consistent with WNT5A loss in human breast cancer, WNT5A expression was evident in preneoplastic mammary gland and early tumors (less than 0.5 cm in diameter with evident features of ductal carcinoma in situ (DCIS; Fig. 3D , gland and early tumor) and was decreased in late-stage tumors (2 cm in diameter) and lung metastasis (Fig. 3D ), in agreement with its tumor-suppressive role (10) .
WNT5A suppresses the growth of basal TIC via a paracrine fashion WNT5A is known to suppress breast cancer (10), whereas it is largely unknown how WNT5A inhibits tumorigenesis. We hypothesize that WNT5A is a potential niche component from luminal epithelial cells to suppress basal TIC expansion, counterbalancing the canonical Wnt ligand in promoting the expansion of basal cells (32, 33) . We used our established scheme (Supple- Supplementary Fig. S4A and S4B). The suspension mammosphere culture system generated significant amount of cell aggregates. Similar phenomenon was noticed in other studies and reviewed (35) . We chose to use a wellestablished Matrigel-based system to grow spheroids as a more relevant ex vivo tumor model (24, 36) . Different doses of WNT5A treatment did not significantly alter the spheroid number from basal TICs ( Supplementary Fig. S4C ), but significantly reduced the spheroid size from basal TICs not from luminal TICs ( Fig. 4A ; Supplementary Fig. S4D ). We also treated basal TICs with different WNT5A doses and found a consistent and dose-dependent decrease in spheroid size (Fig. 4B) S4E , bottom). We found that coculturing basal TICs with WT mLC led to a significant reduction in mean size compared with basal TICs alone ( WT mLC had no impact on luminal TIC-formed spheroids ( Fig.  4C ; Supplementary Fig. S4E ). Coculturing basal TICs with Wnt5a þ/À mLC partially restored spheroid size ( Fig. 4C ; Supplementary Fig. S4E ). We confirmed that WT mLC secreted more WNT5A than Wnt5a þ/À mLC ( Supplementary Fig. S2C ). We also purified mLC from Wnt5a fl/fl mice and cocultured these cells with basal TICs, either treated with adenovirus encoding GFP (Adv-GFP) or adenovirus encoding cre DNA recombinase (Adv-Cre) to deplete WNT5A expression ( Supplementary Fig. S4F , right). We found mLC from Wnt5a fl/fl mice did not form discernable spheroids ( Fig. 4D; Supplementary Fig. S4F ), similarly to mLC from WT mice ( Supplementary Fig. S4E, bottom) . Although Adv-GFP or Adv-Cre treatment had no significant influence on spheroid growth from basal TICs, coculturing with Wnt5a fl/fl mLC significantly reduced spheroid size (Adv-GFP), which was reversed by the Wnt5a deletion with Adv-Cre treatment ( Fig. 4D ; Supplementary Fig. S4F ). These data strongly suggest a specific paracrine signaling pathway mediated by WNT5A of luminal origin in suppressing basal TIC growth. We stained frozen sections from basal TIC-formed spheroids and confirmed that basal TICs were able to form both hollow acinus-like structures as well as solid DCIS-like structures (Supplementary Fig. S4G; ref. 22 ). Most of spheroid cells are positive for luminal epithelial cell marker keratin 8 (KRT8), suggesting the differentiation from basal cells to luminal epithelial cells (Supplementary Fig. S4G ). WNT5A was expressed by most of KRT8 þ luminal cells and was low-to-absent from KRT8-negative cells (Supplementary Fig. S4G ).
We also compared tumor onset days, multiplicity of tumors, and metastasis between ErbB2/WT and ErbB2/Wnt5a þ/À females. Our initial analysis of Wnt5a þ/À females showed no phenotype in mammary gland development based on whole mount ( Supplementary Fig. S5A ), H&E staining (Supplementary Fig. S5B ), as well as the litter size and feeding. Heterozygous deletion of Wnt5a did not affect the primary tumor onset in the ErbB2-induced tumorigenesis (Fig. 5A) . However, heterozygous Wnt5a deletion increased the tumor incidence (Fig.  5B) . We also found that only 1 of 6 ErbB2/WT females had one small lung metastasis by histologic assessment, but 4 of 6 ErbB2/Wnt5a þ/À female mice had lung metastasis with numbers ranging from 2 to 19 ( Fig. 5C and D) .
WNT5A activates SMAD2 in a TGFbR-dependent manner
The TGFb-SMAD signaling pathway induces the expression WNT5A and in turn suppresses mammary morphogenesis and carcinogenesis (10, 15) . We added a TGFbR1 kinase inhibitor SB-431542 together with WNT5A for spheroid growth, with the expectation that WNT5A could suppress spheroid growth when inhibiting TGFb-SMAD. Unexpectedly, we observed a significant size increase in basal TIC-formed spheroids compared with WNT5A alone ( Fig. 4A and B; Supplementary Fig. S4D ), suggesting that TGFb-SMAD is either parallel to or downstream of WNT5A. Luminal TIC-formed spheroids were not affected by WNT5A treatment, but inhibition of TGFb-SMAD significantly increased the mean size from luminal TICs ( Fig. 4A ; Supplementary Fig. S4D ). SB-431542 alone had no significant impact on (Fig. 4B , comparing NT and SB). We purified primary basal cells and luminal cells from preneoplastic mouse mammary gland and confirmed the purity of basal or luminal cells by using KRT5 as a basal-specific marker and KRT8 as a luminal-specific marker (Fig. 6A ). Basal epithelial cells had low level of phosphorylation of SMAD2 (p-SMAD2), whereas luminal cells had constitutively high P-SMAD2 (Fig. 6A) . WNT5A induced p-SMAD2 in basal cells in a TGFbR1-dependent manner because SB-431542 inhibited WNT5A-induced P-SMAD2 (Fig. 6A) . Luminal cells had higher basal level of p-SMAD2 that was not further induced by WNT5A; SB-431542 treatment, either alone or in combination with WNT5A treatment, did not significantly reduce p-SMAD2 signal (Fig. 6A) . We did not observe P-SMAD3 (the lower 52 KD band in third panel, Fig. 6A ). WNT5A was expressed stronger in luminal epithelial cells and significantly less in basal epithelial cells (Fig. 6A) . We confirmed WNT5A-induced P-SMAD2 in HMLE cells (Supplementary Fig. S6A ) and in MCF10A cells ( Supplementary Fig. S6B ), two immortalized human mammary epithelial lines. TGFb induced 4-to 5-fold higher p-SMAD2 than WNT5A in MCF10A cells (Supplementary Fig. S6B; Fig. 6B ).
We found a similar but delayed WNT5A-induced P-SMAD2 and high basal level of p-SMAD3 in MDA-MB-231 cells, a breast cancer cell line (Supplementary Fig. S6C ). We silenced TGFbR1 in MCF10A and found that downregulation of TGFbR1 reduced WNT5A-and TGFb-induced p-SMAD2 (Fig. 6B) , and further confirmed the necessity of TGFbR1 kinase activity by two independent inhibitors SB-341542 and SB-505124 ( Supplementary  Fig. S6A and S6D ). In addition, WNT5A significantly repressed the expression of cyclin D1 and b-catenin, whereas TGFb increased the expression of cell-cycle inhibitors p15 and p21 (Supplementary Fig. S6E ). WNT5A and TGFb induced the repression of some common genes, including antiapoptotic BCL-XL and GATA3 ( Supplementary Fig. S6E ), further supporting a specific yet different role of WNT5A compared with TGFb in mammary epithelial cells.
RYK is a coreceptor for WNT5A induced-SMAD2 activation
We examined the expression of WNT5A receptors and found that RYK mRNA was reduced in primary tumors within the TCGA breast cancer dataset when compared with normal tissues A-D, after 3 weeks, spheroids were photographed and their size in pixels was quantitated with ImageJ ( Ã , P <0.05; ÃÃ , P 0.0042; ÃÃÃÃ , P < 0.0001); mean AE SEM; n ¼ 10-27 spheroids from two independent experiments).
( Supplementary Fig. S7A ). The reduction of RYK mRNA was seen across all four subtypes ( Supplementary Fig. S7B ). The differential expression of WNT5A receptors from luminal and basal cells were examined using the GSE37223 dataset (30) . RYK mRNA was 1.76-fold higher in basal cells than in luminal cells (Supplementary Fig.  S7C ). We confirmed higher RYK expression in KRT8-negative basal cells from human mammary ducts relative to KRT8-positive luminal cells ( Supplementary Fig. S7D ), and observed a significantly loss of RYK expression in adjacent invasive cancer cells ( Supplementary Fig. S7D ). We also found that mouse primary basal cells had higher RYK expression relative to luminal cells (Fig.  6A) . ROR1 mRNA was 4-fold higher in basal cells than in luminal cells ( Supplementary Fig. S7C ). We failed to detect ROR1 protein (data not shown), confirming its nature as a fetal antigen (21). Both ROR2 and FZD4 did not possess significant difference between luminal and basal cells (Supplementary Fig. S7C ; ref. 17) . As nonrelevant FZD members that mediate classical Wnt signaling, FZD6, but not FZD5, was found to be elevated in basal cells relative to luminal cells ( Supplementary Fig. S7C ), supporting the role of paracrine classic Wnt signaling in mammary epithelium (32, 33) . We designed two shRNAs that significantly reduced RYK expression to about 10% relative to MCF10A cells expressing a luciferase-targeting control shRNA (Fig. 7A) . WNT5A induced p-SMAD2 that was lower than TGFb-induced p-SMAD2 (Fig. 7A) . Silencing RYK in MCF10A cells led to a significantly reduced p-SMAD2 induced by WNT5A, and to a lesser extent the TGFb-induced p-SMAD2, relative to parental MCF10A cells (Supplementary Fig.  S8A ) or MCF10A cells expressing control shRNA (Fig. 7A and quantitated in Fig. 7B ). Interestingly, RYK silencing led to significant increase of TGFbR1 (Fig. 7A ) and SMAD2/3 ( Fig. 7A;  Supplementary Fig. S8A ), supporting a potential negative feedback from RYK to SMAD and TGFbR1. We further confirmed a dose-dependent increase of p-SMAD2 in response to WNT5A ranging from 0 to 200 ng/mL, which agrees with the dosedependent suppression of spheroid size (Fig. 4B) and was dependent on RYK expression (Fig. 7C) . Interestingly, RYK deficiency led to a significant JNK activation at both basal and WNT5A-induced levels (Fig. 7C) . These results suggest that RYK preferentially binds to WNT5A to activate p-SMAD2 and RYK deficiency leads to other WNT5A receptor-mediated signaling pathways as recently reported (37) . Mechanistically, we found a constitutive interaction between TGFbR1 and RYK that was further enhanced by WNT5A treatment (Fig. 7D) ; however, TGFb treatment released RYK protein from the TGFbR complex (Fig. 7D) . Anti-RYK antibody failed to pull down TGFbR (data not shown), possibly due to competitive binding to the similar sites on RYK.
Consistently, RYK deficiency in MCF10A cells increased spheroid size and led to an invasive phenotype ( Supplementary Fig.  S8B and S8C ). We analyzed a published GEO dataset GSE2034, including 255 clinical breast cancer specimens. We equally separated the 255 specimens into 4 groups based on the expression of RYK (Supplementary Fig. S8D) or SMAD2 (Supplementary Fig.  S8E ), or interaction between RYK and SMAD2 (Supplementary Fig. S8F; Fig. 7E ). The expression of either RYK or SMAD2 was not correlated with metastasis-free survival (MFS; Supplementary  Fig. S8D and S8E) . We found that patients whose specimens have high expression of both RYK and SMAD2 had the longest time to MFS and those whose specimens have low RYK and SMAD2 had the shortest MFS (Supplementary Fig. S8F ; Fig. 7E , P ¼ 0.006, comparing groups 1/1 with 0/0). This result suggests the functional interaction between RYK and SMAD2 to suppress the progression and metastasis of human cancer.
Discussion
It is essential for cancer biology and therapy to understand how cancer initiates and how TICs evade the normal suppressive microenvironment. Here, we uncover an important paracrine regulation from luminal cell-produced WNT5A, in a TGFbRdependent manner (10) , to suppress the growth of basal TICs, thus tumorigenesis ( Supplementary Fig. S9 ). Fig . S9 ). This unique signaling pathway is important for the growth of basal TICs during ErbB2-induced breast cancer. WNT5A is a downstream effector of TGFb and mediates the suppressive effect of TGFb on mammary morphogenesis and carcinogenesis (10, 15) . Our study identified a feed-forward activation pathway that TGFb induces WNT5A within luminal cells and WNT5A further expands the TFGbR/SMAD signaling in basal cells, for example, basal TIC in the case of breast cancer model, to suppress their growth. It is known that normal tissue microenvironment suppresses uncontrolled proliferation of stem cells and promotes their asymmetrical proliferation (38) . Mammary stem cells are known to proliferate during pregnancy and diestrus stage of estrus cycle mediated by classical Wnt signaling and receptor activator for NF-kB ligand (RANKL), a process activated by luminal progesterone signaling (32, 33) . Coincidentally, both classic Wnt signaling (39) and RANKL (40, 41) are critical to promote carcinogen-or oncogene-induced mammary cancer, although the connection between the expansion of mammary stem cells and cancer promotion is difficult to prove and yet to be established. WNT5A, on the other hand, likely serves a "niche" component to counterbalance classical Wnt or RANKL effects on the expansion of mammary stem cells, that is, the basal TICs, and thus suppresses tumorigenesis. WNT5A plays a broader role in tissue stem cells and its ablation increases proliferative intestinal stem cells (27) . WNT5A functions as a negative regulator of selfrenewal or proliferation in embryonic and hematopoietic stem cells (42, 43) through RYK (44) . Interestingly, in colon WNT5A induces p-SMAD3 not p-SMAD2 in a ROR1/2-dependent manner, suggesting that WNT5A uses a similar mechanism to regulate the homeostasis of tissue stem cells. Among many WNT5A receptors, RYK is highly expressed in normal mammary tissue and decreased in all breast cancer subtypes (Supplementary Fig. S7B ). Our analysis of the Affymetrix array dataset GSE2034 based on 255 human breast cancer specimens further corroborates the role of RYK in suppressing metastasis in conjunction with SMAD2 (Fig. 7E) . A recent study showed that WNT5A promotes mammosphere growth via ROR2-mediated JNK activation (37) . One potential explanation is that WNT5A preferentially interacts with RYK; in the absence of RYK, WNT5A activates JNK1/2 (Fig. 7C ) in an ROR2-dependent manner (37) . It is known that WNT5A induces RANKL expression via ROR2-mediated JNK activation during osteoclastogenesis (45), a potential mechanism that might take place in mammary epithelium, when condition permits, to promote mammary stem cells. Another potential explanation is that we used mammary epithelial cells from preneoplastic MMTVErbB2 female mice. ErbB2 promotes strong activation of the MAPK Erk1/2 pathway for mammary tumorigenesis, thus surpasses the necessity of JNK activation as seen in normal mammary epithelial cells or those from MMTV-Wnt1 transgenic mice (37) . Indeed, genetic deletion of JNK in mammary epithelial cells led to increased ductal morphogenesis and mammary tumorigenesis, suggesting its tumor suppressive role in mammary cancer (46) .
The paracrine interactions between basal and luminal compartments within the mammary epithelium have broader implications. We reported here that WNT5A is highly expressed in luminal cells and inhibits the growth of basal TICs, which likely needs to evade the WNT5A-mediated or other suppressive microenvironment signals during the oncogenic process. We believe that basal TICs have to undergo luminal differentiation during ErbB2-induced mammary tumorigenesis because all ErbB2-induced tumors express luminal keratins (22) . During the basal to luminal differentiation, WNT5A perceivably loses its control on tumor cells as evidenced by the fact that WNT5A failed to induce further p-SMAD2 in ErbB2 þ luminal cells (Fig. 6A) . It is known that Notch activation leads to the commitment of mammary stem cells to luminal differentiation during Notch-induced tumorigenesis (47 RYK is the coreceptor for WNT5A-induced activation of SMAD2. A and B, MCF10A cells were infected with lentiviral particles encoding control luciferase shRNA (shCON) or two independent RYK shRNAs with coexpression of GFP. GFP-positive cells were collected by flow cytometry. Parental MCF10A (data not shown here), MCF10A cells with control shRNA, or cells with RYK shRNA1 or shRNA2 were cultured and either left untreated (NT) or treated with WNT5A (100 ng/mL) or TGFb (5 ng/mL). Cell lysates were collected, separated by SDS-PAGE, and immunoblotted with the indicated antibodies. Representative images are shown in A and quantitated in B; P < 0.01; n ¼ 3. C, MCF10A cells with control shRNA or cells with RYK shRNA1 were treated with different amount of WNT5A as indicated for 0.5 or 1 hour. Cell lysates were collected, followed by immunoblotting with the indicated antibodies. D, MCF10A cells were treated with WNT5A (100 ng/mL) or TGFb1 (5 ng/mL) for 1 hour. Cells were lysed and lysates were immunoprecipitated with anti-RYK and anti-TGFbR1 antibodies. Immunocomplex was resolved by SDS-PAGE, followed by immunoblotting with the indicated antibodies. E, the Affymetrix GEO dataset GSE2034 containing 255 human breast cancer specimens with supplemented clinical records was downloaded. Two hundred and fifty-five specimens in GSE2034 were separated into four groups based on the expression level of RYK and SMAD2. Low (assigned as 0) and high (assigned as 1) expression of RYK or SMAD2 were defined as expression values lower or higher than median values; N, numbers; a P value comparing 1/1 group versus 0.0 group is indicated. The correlation between MFS and RYK/SMAD2 expression was analyzed and Kaplan-Meier curve was graphed using Prism 6 software. Resources of the NIH under Award Number 1S10 RR027219. Finally, these results here are in whole or part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov/).
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